Withings Receives FDA Clearance for BeamO Multi-Function Health Device Combining ECG, Stethoscope, and Thermometer
核心洞察
Withings has received FDA clearance for BeamO (搜索), a revolutionary health monitoring device that combines electrocardiogram, digital stethoscope, and thermometer functions in a single portable unit.
The device enables at-home measurement of vital signs typically assessed during medical consultations, performing complete health check-ups in under one minute for enhanced telehealth capabilities.
BeamO (搜索) is now available in the US for $249.95 exclusively through Withings.com, with plans for Amazon and retail partner availability in early 2026.
Withings announced that the FDA has cleared BeamO (搜索), a groundbreaking health monitoring device that transforms traditional temperature measurement into comprehensive vital sign assessment. The device combines electrocardiogram sensors, digital stethoscope capabilities, and contactless thermometry in a single portable unit, enabling at-home measurements of cardiac, pulmonary, and temperature indicators typically evaluated during medical consultations.
Revolutionary Multi-Sensor Technology
BeamO (搜索) integrates three distinct medical measurement capabilities through innovative miniaturization. Two stainless steel electrodes positioned on the device's side enable medically certified 1-lead electrocardiogram measurements for adults aged 22 and older, with real-time results displayed on an animated color LED screen. The device captures heart (搜索) electrical activity through simple grip activation, completing measurements in under one minute.
The digital stethoscope function utilizes a piezoelectric disc to capture acoustic sound waves from the chest or back, providing precise heart (搜索) and lung measurements. Users can listen to results via headphones using the included USB-C to jack adapter, with audio streaming capabilities allowing doctors to guide device placement during teleconsultations.
For temperature measurement, BeamO (搜索) employs contactless analysis of the temporal artery (搜索), representing what the company describes as a significant technological advancement that increases scan sensitivity and reduces variability from distance variations during forehead measurements.
Clinical Development and AI Integration
Xavier Debreuil, Product Research Director at Withings, explained the device's sophisticated sensor array: "These sensors record the heart (搜索)'s electrical activity as well as measure infrared light to interpret body temperature. On the other hand, they capture acoustic waves to study the activity of the heart and lungs (搜索). All the data is analyzed by artificial intelligence algorithms to identify anomalies."
The device was clinically developed in collaboration with renowned hospitals and institutions, with six patent applications supporting its technological innovations. BeamO (搜索) addresses significant health monitoring needs, particularly given that 8.6% of U.S. adults and 6.5% of U.S. children currently have asthma (搜索), while 5% of adults are affected by acute bronchitis (搜索) annually.
Enhanced Telehealth Integration
BeamO (搜索)'s capabilities are enhanced through HealthLink, a secure feature within the Withings app that generates clinician-ready web links for sharing comprehensive patient data, including detailed BeamO measurements. This functionality significantly improves virtual care quality by ensuring doctors receive complete patient information remotely and securely.
The device supports Cardio Check-Up services through Withings+ subscription, providing detailed cardiac health assessments conducted by board-certified cardiologists within 24 hours. Eric Carreel, Founder and President of Withings, emphasized the device's impact: "This data promotes a much more precise and reliable diagnosis, and it marks a revolution in telemedicine, transforming it into a true medical consultation by integrating the data collection component."
Market Availability and Pricing
BeamO (搜索) is available for purchase in the US starting November 13, 2025, exclusively through withings.com at $249.95. Each purchase includes a complimentary one-month Withings+ subscription and one free Cardio Check-Up token. The device will expand to Amazon and select retail partners across the US in early 2026.
The Withings+ subscription, priced at $10 monthly or $100 annually, provides additional features including long-term health assessments, weekly health breakdowns, ECG-powered cardiologist reviews every 90 days, auto-trends detection, and daily vitality indicators.
Clinical Applications and Limitations
While BeamO (搜索) enables comprehensive vital sign monitoring, the company emphasizes that the digital stethoscope feature is not intended for diagnosis, treatment, or monitoring, but rather for recording and sharing with healthcare professionals. The device cannot detect or treat conditions like bronchitis (搜索) or asthma (搜索), though lung recordings can support long-term care when shared with doctors.
The device automatically syncs with the Withings application via Wi-Fi or Bluetooth, facilitating continuous health data collection and enabling users to build comprehensive medical records easily shared with caregivers through generated health reports.